NYSE · SOLV
Healthcare · Medical - Care Facilities
$81.33
Down-$2.23 (-2.67%)
Updated Nov 1, 2026, 12:29 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · SOLV
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SOLV closed at $81.33 after 20 trading sessions, down 7.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $84.15 | $84.48 | $80.76 | $81.33 | 1.07M |
| Oct 29, 2026 | $82.27 | $83.68 | $82.25 | $83.56 | 1.09M |
| Oct 28, 2026 | $83.08 | $83.33 | $81.38 | $81.85 | 1.57M |
| Oct 27, 2026 | $85.36 | $85.81 | $82.85 | $82.98 | 1.32M |
| Oct 26, 2026 | $85.68 | $87.56 | $85.68 | $85.81 | 975.57K |
| Oct 23, 2026 | $86.92 | $87.27 | $84.81 | $85.41 | 1.66M |
| Oct 22, 2026 | $86.89 | $87.87 | $86.42 | $87.45 | 769.89K |
| Oct 21, 2026 | $85.74 | $86.88 | $85.35 | $86.67 | 812.8K |
| Oct 20, 2026 | $86.01 | $86.72 | $85.205 | $86.39 | 804.54K |
| Oct 19, 2026 | $85.31 | $86.25 | $85.04 | $85.05 | 850.96K |
| Oct 16, 2026 | $88.42 | $89.00 | $85.18 | $85.81 | 1.17M |
| Oct 15, 2026 | $88.81 | $89.45 | $87.255 | $87.86 | 1.15M |
| Oct 14, 2026 | $86.49 | $87.45 | $85.94 | $87.26 | 1.03M |
| Oct 13, 2026 | $86.01 | $86.49 | $83.29 | $86.30 | 985K |
| Oct 12, 2026 | $87.00 | $88.265 | $84.42 | $85.31 | 1.45M |
| Oct 9, 2026 | $86.66 | $88.23 | $86.66 | $87.29 | 1.06M |
| Oct 8, 2026 | $85.80 | $86.79 | $85.25 | $86.41 | 1.29M |
| Oct 7, 2026 | $85.62 | $87.25 | $85.30 | $85.88 | 981.19K |
| Oct 6, 2026 | $88.45 | $88.93 | $86.895 | $87.04 | 914.16K |
| Oct 5, 2026 | $87.52 | $88.395 | $86.7401 | $88.03 | 1.04M |
The latest Smart Investors Daily articles mentioning SOLV.
Company
Market Activity
Research & News
SOLV research
Company profile and research snapshot.
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | BTIG | Buy | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | Piper Sandler | Overweight | — |
| Aug 6, 2026 | UBS | Buy | — |
| Aug 6, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Elevance Health (ELV) delivered earnings and revenue surprises of +50.00% and +4.01%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 19, 2026
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.® Therapy*. Following Solventum's acquisition of Acera Surgical in December 2025, this regulatory milestone brings two advanced technologies together into one path to support active wound healing.
Benzinga · Oct 19, 2026
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber
Yahoo · Oct 15, 2026
Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SOLV.
